LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Kodu・Aktsiate loetelu・Heron Therapeutics Inc

Heron Therapeutics Inc

Suletud

SektorTervishoid

0.4 -2.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.39

Max

0.41

Põhinäitajad
By Trading Economics
Sissetulek	-5.2M -8.1M
Müük	-5.9M 35M
Aktsiakasum	-0.04
Kasumimarginaal	-23.367
Töötajad	128
EBITDA	-4M -4.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+344.44% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-144M 86M
Eelmine avamishind	2.84
Eelmine sulgemishind	0.4

Uudiste sentiment

By Acuity

50%

153 / 344 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. juuni 2026, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. juuni 2026, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. juuni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. juuni 2026, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. juuni 2026, 20:51 UTC

Tulu

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. juuni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. juuni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. juuni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. juuni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. juuni 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. juuni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. juuni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. juuni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. juuni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. juuni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. juuni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. juuni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

344.44% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 344.44%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

153 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.